The Societe Generale Reiterates Hold Rating for Novartis AG (NVS)

The Societe Generale Reiterates Hold Rating for Novartis AG (NVS)

Novartis AG (NYSE:NVS)‘s stock had its “hold” rating reissued by investment analysts at Societe Generale in a research report issued on Thursday.

Other equities analysts have also recently issued research reports about the company. Jefferies Group restated a “buy” rating on shares of Novartis AG in a report on Sunday, October 16th. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis AG in a report on Monday, October 10th. Chardan Capital decreased their price target on Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a report on Monday, October 10th. Zacks Investment Research upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a report on Monday, July 11th. Finally, Argus restated a “hold” rating on shares of Novartis AG in a report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Novartis AG has a consensus rating of “Hold” and a consensus target price of $89.20.

Novartis AG (NYSE:NVS) opened at 71.07 on Thursday. Novartis AG has a one year low of $69.90 and a one year high of $91.15. The firm has a market capitalization of $168.83 billion, a PE ratio of 25.06 and a beta of 0.57. The stock has a 50 day moving average of $77.83 and a 200-day moving average of $79.01.

Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 25th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.19 by $0.04. The firm earned $12.13 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. Novartis AG’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.27 EPS. On average, equities analysts predict that Novartis AG will post $4.73 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Dearborn Partners LLC boosted its position in shares of Novartis AG by 3.1% in the second quarter. Dearborn Partners LLC now owns 342,484 shares of the company’s stock valued at $28,258,000 after buying an additional 10,427 shares during the period. Bartlett & Co. LLC boosted its position in shares of Novartis AG by 1.2% in the second quarter. Bartlett & Co. LLC now owns 446,714 shares of the company’s stock valued at $36,858,000 after buying an additional 5,270 shares during the period. Compass Capital Management Inc. boosted its position in shares of Novartis AG by 15.3% in the second quarter. Compass Capital Management Inc. now owns 247,197 shares of the company’s stock valued at $20,396,000 after buying an additional 32,845 shares during the period. Royal Bank of Canada boosted its position in shares of Novartis AG by 1.8% in the first quarter. Royal Bank of Canada now owns 1,070,573 shares of the company’s stock valued at $77,553,000 after buying an additional 18,714 shares during the period. Finally, Woodley Farra Manion Portfolio Management Inc. purchased a new position in shares of Novartis AG during the second quarter valued at about $26,632,000. Hedge funds and other institutional investors own 9.78% of the company’s stock.

About Novartis AG

Related posts

Leave a Comment